Stock DNA
Pharmaceuticals & Biotechnology
DKK 1,040,939 Million ()
11.00
NA
3.79%
-0.23
61.08%
6.13
Revenue and Profits:
Net Sales:
76,857 Million
(Quarterly Results - Jun 2025)
Net Profit:
26,503 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
379.26%
0%
379.26%
6 Months
374.85%
0%
374.85%
1 Year
454.44%
0%
454.44%
2 Years
621.34%
0%
621.34%
3 Years
524.45%
0%
524.45%
4 Years
793.51%
0%
793.51%
5 Years
477.72%
0%
477.72%
Novo Nordisk A/S for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
19.93%
EBIT Growth (5y)
19.86%
EBIT to Interest (avg)
18.19
Debt to EBITDA (avg)
0.11
Net Debt to Equity (avg)
0.56
Sales to Capital Employed (avg)
1.66
Tax Ratio
20.93%
Dividend Payout Ratio
50.28%
Pledged Shares
0
Institutional Holding
0.03%
ROCE (avg)
84.59%
ROE (avg)
69.89%
Valuation key factors
Factor
Value
P/E Ratio
11
Industry P/E
Price to Book Value
7.38
EV to EBIT
9.13
EV to EBITDA
8.22
EV to Capital Employed
5.32
EV to Sales
4.24
PEG Ratio
0.47
Dividend Yield
3.18%
ROCE (Latest)
58.27%
ROE (Latest)
66.09%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Bearish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Mildly Bullish
Bearish
Dow Theory
No Trend
No Trend
OBV
No Trend
No Trend
Shareholding Snapshot : Mar 2024
Shareholding Compare (%holding) 
Majority shareholders
Foreign Institutions
Domestic Funds
Held in 0 Schemes (0%)
Foreign Institutions
Held by 13 Foreign Institutions (0.05%)
Strategic Entities with highest holding
Highest Public shareholder
Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY
Jun'25
Jun'24
Change(%)
Net Sales
76,857.00
68,060.00
12.93%
Operating Profit (PBDIT) excl Other Income
38,305.00
34,374.00
11.44%
Interest
4,958.00
1,562.00
217.41%
Exceptional Items
0.00
0.00
Consolidate Net Profit
26,503.00
20,050.00
32.18%
Operating Profit Margin (Excl OI)
435.50%
375.10%
6.04%
USD in Million.
Net Sales
YoY Growth in quarter ended Jun 2025 is 12.93% vs 25.34% in Jun 2024
Consolidated Net Profit
YoY Growth in quarter ended Jun 2025 is 32.18% vs 3.20% in Jun 2024
Annual Results Snapshot (Consolidated) - Dec'24
Dec'24
Dec'23
Change(%)
Net Sales
290,403.00
232,261.00
25.03%
Operating Profit (PBDIT) excl Other Income
147,948.00
111,383.00
32.83%
Interest
1,929.00
739.00
161.03%
Exceptional Items
-6,204.00
-70.00
-8,762.86%
Consolidate Net Profit
100,988.00
83,683.00
20.68%
Operating Profit Margin (Excl OI)
480.00%
445.10%
3.49%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2024 is 25.03% vs 31.26% in Dec 2023
Consolidated Net Profit
YoY Growth in year ended Dec 2024 is 20.68% vs 50.71% in Dec 2023
About Novo Nordisk A/S 
Novo Nordisk A/S
Pharmaceuticals & Biotechnology
Novo Nordisk A/S is a global healthcare company engaged in diabetes care. The Company is also engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The Company operates through two business segments: diabetes and obesity care, and biopharmaceuticals. The Company's diabetes and obesity care segment covers insulin, GLP-1, other protein-related products, such as glucagon, protein-related delivery systems and needles, and oral anti-diabetic drugs. The Company's biopharmaceuticals segment covers the therapy areas of hemophilia care, growth hormone therapy and hormone replacement therapy. The Company also offers Saxenda product to treat obesity. It offers a range of products, including NovoLog/NovoRapid; NovoLog Mix/NovoMix; Prandin/NovoNorm; NovoSeven; Norditropin, and Vagifem. As of December 31, 2016, it marketed its products in over 180 countries. Its regional structure consists of two commercial units: North America and International Operations.
Company Coordinates 
Company Details
Novo Alle 1 , BAGSVAERD None : 2880
Registrar Details






